![an image of the nervous system](/global/pharmaceuticals/common/img/cns_disorders/cns_disorders_01.jpg)
Modern medicine recognizes a growing number of mental disorders linked to the central nervous system (CNS). Meiji has decades of expertise in this field, launching some of Japan's earliest antidepressants and anti-anxiety drugs, including the first selective serotonin reuptake inhibitor in 1999.
Therapeutic Areas
-
Schizophrenia
-
Depression
-
Dravet syndrome
-
Insomnia
-
Panic disorder
-
Post-traumatic stress disorder
-
Obsessive-compulsive disorder
-
Our Approach to Rare and Common CNS Disorders
CNS disorders are on the rise due to factors such as aging, lifestyle changes, and stress. Effectively treating such a wide range of conditions is a challenge for many societies. Meiji Seika Pharma's primary focus is on new treatments for depression and schizophrenia, as well as Dravet syndrome, a rare form of epilepsy of unknown cause. At the same time, the company supplies generic drugs for widespread conditions such as Alzheimer's.
Find out more from our wellness stories
![an image of bacteria that cause infections](/global/pharmaceuticals/common/img/cns_disorders/cns_disorders_14.jpg)
Hope for Patients with Dravet Syndrome
Read how Meiji Seika Pharma supports patients with Dravet syndrome, a rare form of epilepsy that first appears in infancy.
Areas of Focus
Have a question?
Contact us here.
CONTACT US
Meiji Seika Pharma Co., Ltd.
Based in Japan, we are a leading developer and manufacturer of antibacterial drugs, vaccines and biotech solutions, with a history of over 75 years.
Location
- Headquarters
2-4-16 Kyobashi, Chuo-ku, Tokyo104-8002 Japan